Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Remedy Q4'25: High stakes in play this year

REMEDYResearch2026-02-11 12:02
Atte RiikolaAnalyst
Discuss
Download report (PDF)

Summary

  • Remedy's Q4 revenue increased by 46% to 17.0 MEUR, surpassing the 16.2 MEUR estimate, with EBITDA also exceeding expectations at 3.9 MEUR.
  • The upcoming release of Control Resonant is crucial for Remedy's financial performance, with projected sales of 1.8 million copies in 2026 and 2.2 million in 2027, potentially boosting revenue to over 120 MEUR.
  • Remedy's valuation is considered attractive due to its growth and profitability potential, with a DCF model baseline scenario valuing the company at EUR 22.7 per share.
  • The successful release of Control Resonant is expected to enhance Remedy's share price and enable self-financing of future projects, with valuation multiples moderating in the coming years.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 2/11/2026 at 7:00 am EET.

Remedy's investment story is entering a pivotal year, as the company is about to release what is arguably the most important game in its history in terms of commercial success and, in our view, also its most promising game. We believe Control Resonant will sell well, and the upcoming release will also contribute to the stock's valuation, which has recently come under pressure due to fears about AI that, in our opinion, have somewhat unjustifiably affected gaming stocks as well. No game, no fame. We reiterate our EUR 19.0 target price and raise our recommendation to Buy (previously Accumulate). 

Q4 figures landed slightly above our expectations

Remedy’s Q4 revenue grew by 46% to 17.0 MEUR, which exceeded our 16.2 MEUR estimate. The increase in revenue was also reflected in the earnings figures, and EBITDA (3.9 MEUR) was a bit better than our estimate (3.2 MEUR). Development fees for the quarter (8.7 MEUR) were slightly lower than our expectations, while own game sales and royalties (8.4 MEUR) came as a positive surprise. This growth was supported by the availability of Alan Wake 2 on PS Plus in October and FBC: Firebreak's B2B payments. Additionally, Remedy highlighted the sales of the original Control game as a factor in the growth. The game, which is over six years old, still sold over one million copies overall last year. Naturally, the game's average price has been very low, yet million-level sales can still be considered good performance for an old game. This will also help grow the audience for the upcoming sequel.

Control Resonant will determine this year’s development

As expected, Remedy provided guidance on revenue and EBITDA growth for 2026. The wording of the guidance remains cautious as, according to our calculations, both revenue and EBITDA should grow significantly following the successful launch of Control Resonant. Understandably, the company wants to be cautious at this stage, as uncertainty prior to the game's release is naturally high, even though the initial reception among players seems promising. The game's Steam wishlist ranking (currently 67th) has also developed well. Following the Q4 report, we have not made any significant changes to our forecasts and still expect the game to be released at the end of Q2'26. We also consider it very possible that the release will be in Q3. We forecast Control Resonant to sell roughly 1.8 million copies in 2026 and about 2.2 million copies in 2027. As a result, we estimate Remedy's revenue to exceed 120 MEUR in 2026-2027, with EBITDA reaching ~19-26 MEUR. The starting points for strong game sales are good, as the original Control has sold over 5 million copies, and over 20 million players have played the game across
various platforms.

We expect Control Resonant to boost the share price

We believe in Remedy’s ability to create multiple high-quality and successful games in the long term, and considering the growth and profitability potential this offers, the company's current valuation is attractive. The long-term potential is indicated by the value of the baseline scenario of the DCF model (EUR 22.7). For Remedy's share value creation, it is essential for the company to succeed with the release of Control Resonant. A successful release would essentially enable the company to finance and publish its next projects itself. It would also further strengthen the value of the Control game brand. Remedy's valuation multiples will also moderate in the coming years (2026e-2027e EV/S about 1.5x and EV/EBITDA 10x-7x), though they will continue to fluctuate with the timing of future game releases as well. Overall, Control Resonant will generate positive news for Remedy in 2026, in addition to the approaching release of the Max Payne Remake. We believe that Remedy's stock will be supported by these major upcoming game releases, and in a good scenario, the potential is significant.

Remedy Entertainment is a game developer. Its operations are primarily focused on the development of action games, with a particular focus on 3D technology. Examples of games that the company has developed include several different versions of Alan Wake, Max Payne, and Control. Remedy also develops its own game engine and tooling technology that powers many of its games. The company was founded in 1995 and is headquartered in Espoo, Finland.

Read more on company page

Key Estimate Figures10/02

202526e27e
Revenue59.5122.5121.3
growth-%17.5 %105.9 %-1.0 %
EBIT (adj.)-14.9-0.512.2
EBIT-% (adj.)-25.0 %-0.4 %10.1 %
EPS (adj.)-0.96-0.060.70
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.21.6
EV/EBITDA17.29.97.0

Forum discussions

By the way, I came across this article, which revealed new information that Resonant stayed pretty well within its €50M production budget—or...
3 hours ago
13
Yep. Even though people joked about it back in the day, the entire industry was ultimately completely right to avoid this November release window...
3 hours ago
10
That review average for GTA 6 is just insane, so if Resonant snags several runner-up spots, you really just have to be happy with that. Other...
3 hours ago
by Arvuuttaja
1
Exactly. Control Resonant isn’t nominated in any category where GTA6 isn’t. If GTA6 sweeps all the trophies, Remedy will be left with nothing...
3 hours ago
by Vinski74
1
Because GTA is taking up absolutely all the media space right now, and the same will continue at the Awards when it wins GOTY.
4 hours ago
by supremegod
2
Great news for Remedy! A tied second place in the nominations—you’d think that would have some impact on visibility and the game’s sales. Surprisingly...
4 hours ago
by Vinski74
1
I can only imagine how proud they must be at Remedy for this achievement! The GOTY vote actually includes pretty much the exact games I’m interested...
21 hours ago
by Thiebault
37